SCHEMBL9549

SCHEMBL9549

COC(=O)c1ccccc1-c1ccccc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.57
SLC6A4 P31645 3/20 0.57
TSHR P16473 2/20 0.55
LMNA P02545 1/20 0.55
SLC6A2 P23975 1/20 0.54
ALDH1A1 P00352 3/20 0.53
CFTR P13569 1/20 0.53
HSD17B10 Q99714 1/20 0.53
KDM4E B2RXH2 3/20 0.52
POLB P06746 1/20 0.52
ATM Q13315 1/20 0.52
MYC P01106 1/20 0.50
NR4A2 P43354 1/20 0.50
MAPT P10636 3/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 1/20 0.49
HTT P42858 1/20 0.49
MAPK10 P53779 1/20 0.49
PTK2B Q14289 1/20 0.49
NCOA1 Q15788 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL27492792 0.96 SLC6A3 (0.54) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL2267132 0.94 SLC6A3 (0.51) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL69464 0.90 SLC6A3 (0.67) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL28138154 0.87 TSHR (0.50) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL12928420 0.87 SLC6A3 (0.57) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL6906782 0.86 MYC (0.47) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL28249154 0.85 SLC6A3 (0.49) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL12724753 0.85 SLC6A3 (0.57) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL24390974 0.84 TSHR (0.57) SLC6A3SLC6A4TSHRLMNASLC6A2
SCHEMBL30285193 0.84 SLC6A3 (0.58) SLC6A3SLC6A4TSHRLMNASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117534987-A Dual-mode orthogonal multicolor fluorescence security anti-counterfeiting ink and preparation method thereof 内蒙古工业大学 2024-02-09 CN disclosed
US-20150255730-A1 BIPHENYL DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2015-09-10 US disclosed
EP-0986384-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2004-09-15 EP disclosed
EP-0986384-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 2000-03-22 EP disclosed
WO-1998050029-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 WO disclosed
WO-1998050030-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 WO disclosed
EP-0733366-B1 Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics DU PONT (US) 1998-04-01 EP disclosed
EP-0324377-B1 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids DU PONT (US) 1997-04-16 EP disclosed
EP-0733366-A2 Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-09-25 EP disclosed
EP-0253310-B1 Angiotensin II receptor blocking imidazoles DU PONT (US) 1994-10-26 EP disclosed
US-5256781-A Anticholesterol, antilipemic, hypotensive agents AMERICAN HOME PRODUCTS CORPORATION (US) 1993-10-26 US disclosed
US-5236925-A Hypotensive agents, treatment of congestive heart failure AMERICAN HOME PRODUCTS CORPORATION (US) 1993-08-17 US disclosed
WO-1993008170-A1 SUBSTITUTED HETEROCYCLES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-29 WO disclosed
US-5187168-A Hypotensive agents AMERICAN HOME PRODUCTS CORPORATION (US) 1993-02-16 US disclosed
US-5155118-A Administering angiotensin inhibitor E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-10-13 US disclosed
US-5153197-A Treatment of hypertension with angiotensin II blocking imidazoles E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-10-06 US disclosed
US-5138069-A Treating hypertension and congestive heart failure E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-08-11 US disclosed
US-5128355-A Hypotensive E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-07-07 US disclosed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 EP disclosed
EP-0253310-A2 Angiotensin II receptor blocking imidazoles E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150255730-A1 BIPHENYL DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE NPY5R, AFF1, KCNA5 SLC6A3 2305/4885SLC6A4 2679/4885TSHR 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.